Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
YS Stock Forecast 2025-2026
$1.17
Current Price
$192.09M
Market Cap
Buy 0
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to YS Price Targets
+348.7%
To High Target of $5.25
+256.4%
To Median Target of $4.17
+165.0%
To Low Target of $3.10
YS Price Momentum
0.0%
1 Week Change
-22.0%
1 Month Change
+23.2%
1 Year Change
-67.6%
Year-to-Date Change
-86.4%
From 52W High of $8.60
+223.8%
From 52W Low of $0.36
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Ys Biopharma (YS) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on YS and similar high-potential opportunities.
Latest YS Stock Price Targets & Analyst Predictions
YS has shown a year-to-date change of -67.6% and a 1-year change of 23.2%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for YS. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
YS Analyst Ratings
0
Buy
0
Hold
0
Sell
YS Price Target Range
Low
$3.10
Average
$4.17
High
$5.25
Current: $1.17
Latest YS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for YS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 13, 2023 | Noble Capital Markets | Gregory Aurand | Outperform | Initiates | $5.25 |
Ys Biopharma Co Ltd. (YS) Competitors
The following stocks are similar to Ys Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Ys Biopharma Co Ltd. (YS) Financial Data
Ys Biopharma Co Ltd. has a market capitalization of $192.09M with a P/E ratio of -0.4x. The company generates $75.03M in trailing twelve-month revenue with a -66.8% profit margin.
Revenue growth is -9.2% quarter-over-quarter, while maintaining an operating margin of -49.5% and return on equity of -77.8%.
Valuation Metrics
Market Cap
$192.09M
Enterprise Value
$59.23M
P/E Ratio
-0.4x
PEG Ratio
-4.1x
Price/Sales
0.4x
Growth & Margins
Revenue Growth (YoY)
-9.2%
Gross Margin
+81.9%
Operating Margin
-49.5%
Net Margin
-66.8%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+204.4%
Current Ratio
0.9x
Debt/Equity
117.6x
ROE
-77.8%
ROA
-10.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Ys Biopharma Co Ltd. (YS) Business Model
About Ys Biopharma Co Ltd.
What They Do
Develops vaccines and therapeutic biologics.
Business Model
The company generates revenue through the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics targeting infectious diseases and cancer. By leveraging its proprietary PIKA immunomodulating technology platform, YS Biopharma aims to create innovative products, including rabies and COVID-19 vaccines.
Additional Information
Founded in 2002 and headquartered in Beijing, China, YS Biopharma operates in multiple countries, including the United States and Singapore, positioning itself strategically to access diverse markets for its biopharmaceutical products.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
773
CEO
Dr. Hui Shao C.F.A., M.B.A., Ph.D.
Country
China
IPO Year
2021
Website
www.ysbiopharm.comYs Biopharma Co Ltd. (YS) Latest News & Analysis
Latest News
Quick Summary
YS Biopharma Co., Ltd. announced news from Gaithersburg, Md., on May 24, 2024. Further details were not provided in the excerpt.
Why It Matters
YS Biopharma's announcement may signal developments in biotechnology or drug advancements, potentially impacting stock performance and market sentiment in the biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
YS Biopharma Co., Ltd. announced news on May 21, 2024, from Gaithersburg, Md. Further details on the announcement were not provided in the excerpt.
Why It Matters
YS Biopharma's announcement may indicate new developments or products impacting its market position, potentially affecting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
YS Biopharma Co., Ltd. announced news from Gaithersburg, Md., on May 7, 2024. Further details were not provided in the excerpt.
Why It Matters
YS Biopharma's developments may impact biotech sector valuations, investor sentiment, and stock performance, especially if they announce breakthroughs or partnerships.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
YS Biopharma Co., Ltd. announced news from Gaithersburg, Md. on April 29, 2024. Further details on the announcement were not provided in the excerpt.
Why It Matters
YS Biopharma's news could indicate developments in biopharmaceuticals, influencing stock performance, market sentiment, and potential investment opportunities in the biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
YS Biopharma Co., Ltd. (NASDAQ:YS) will host its Q3 2024 Earnings Conference Call on April 19, 2024, at 8:00 AM ET, featuring key executives including the CEO and CFO.
Why It Matters
YS Biopharma's Q3 earnings call signals key financial insights and future outlook, which can influence stock performance and investor confidence.
Source: Seeking Alpha
Market Sentiment:
Neutral
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
1 year ago
Quick Summary
YS Biopharma Co., Ltd. announced news from Gaithersburg, Md., on April 19, 2024. Details of the announcement were not provided in the excerpt.
Why It Matters
YS Biopharma's announcement could signal developments in biotech, impacting stock prices and investor sentiment in the sector. Watch for potential innovations or partnerships.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About YS Stock
What is Ys Biopharma Co Ltd.'s (YS) stock forecast for 2025?
Based on our analysis of 1 Wall Street analysts, Ys Biopharma Co Ltd. (YS) has a median price target of $4.17. The highest price target is $5.25 and the lowest is $3.10.
Is YS stock a good investment in 2025?
Analyst ratings for YS are not currently available. The stock is currently trading at $1.17. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for YS stock?
Wall Street analysts predict YS stock could reach $4.17 in the next 12 months. This represents a 256.4% increase from the current price of $1.17. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ys Biopharma Co Ltd.'s business model?
The company generates revenue through the discovery, development, manufacturing, and commercialization of vaccines and therapeutic biologics targeting infectious diseases and cancer. By leveraging its proprietary PIKA immunomodulating technology platform, YS Biopharma aims to create innovative products, including rabies and COVID-19 vaccines.
What is the highest forecasted price for YS Ys Biopharma Co Ltd.?
The highest price target for YS is $5.25 from Gregory Aurand at Noble Capital Markets, which represents a 348.7% increase from the current price of $1.17.
What is the lowest forecasted price for YS Ys Biopharma Co Ltd.?
The lowest price target for YS is $3.10 from at , which represents a 165.0% increase from the current price of $1.17.
What is the overall YS consensus from analysts for Ys Biopharma Co Ltd.?
Analyst ratings for YS are not currently available. The stock is trading at $1.17.
How accurate are YS stock price projections?
Stock price projections, including those for Ys Biopharma Co Ltd., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 15, 2025 6:31 PM UTC